Astria Therapeutics (NASDAQ:ATXS – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They currently have a $16.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 117.10% from the company’s current price.
Separately, Oppenheimer upped their target price on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Astria Therapeutics has an average rating of “Buy” and an average target price of $25.60.
Astria Therapeutics Trading Down 1.2 %
Institutional Investors Weigh In On Astria Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of ATXS. Bank of New York Mellon Corp grew its position in Astria Therapeutics by 6.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 139,071 shares of the biotechnology company’s stock worth $1,266,000 after acquiring an additional 8,965 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Astria Therapeutics by 4.1% during the second quarter. Rhumbline Advisers now owns 65,375 shares of the biotechnology company’s stock valued at $595,000 after purchasing an additional 2,556 shares during the period. Quest Partners LLC grew its holdings in shares of Astria Therapeutics by 3,310.6% in the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 3,112 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Astria Therapeutics by 1,043.7% in the second quarter. Dimensional Fund Advisors LP now owns 146,158 shares of the biotechnology company’s stock worth $1,330,000 after buying an additional 133,379 shares during the period. Finally, Sofinnova Investments Inc. bought a new stake in Astria Therapeutics during the 2nd quarter valued at $552,000. Institutional investors own 98.98% of the company’s stock.
About Astria Therapeutics
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
Featured Stories
- Five stocks we like better than Astria Therapeutics
- Pros And Cons Of Monthly Dividend Stocks
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- Want to Profit on the Downtrend? Downtrends, Explained.
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Astria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.